ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,642.10
0.48%
S&P ASX All Technology
2,961.90
0.69%
Brent Oil
86.685
-0.34%
US Dollar vs AUD
1.55707
0.27%
Bitcoin
63,147.57
3.04%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) News

ESPR Esperion Therapeutics Inc

1.82
-0.02 (-1.09%)
Last Updated: 04:44:15
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Esperion Therapeutics Inc ESPR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.02 -1.09% 1.82 04:44:15
Open Price Low Price High Price Close Price Previous Close
1.86 1.81 2.03 1.84
more quote information »

Recent News

Date Time Source Heading
08/4/202404:45GLOBEEsperion Presents Important New Data from CLEAR Outcomes at..
01/4/202423:00GLOBEEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
26/3/202423:00GLOBEEsperion to Participate in 23rd Annual Needham Virtual..
26/3/202407:00GLOBEEsperion Announces Data from CLEAR Outcomes Sub-Groups as..
23/3/202409:26BWU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL®..
23/3/202406:10GLOBEU.S. FDA Approves Broad New Labels for NEXLETOL® and..
23/3/202402:04GLOBECHMP Issues Positive Opinions For Both Bempedoic Acid And..
28/2/202401:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202423:23EDGAR2Form 8-K - Current report
27/2/202422:00GLOBEEsperion Reports Fourth Quarter and Full Year 2023 Financial..
17/2/202408:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
15/2/202406:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202400:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:00GLOBEEsperion to Report Fourth Quarter and Full Year 2023..
02/2/202406:00GLOBERFK, Esperion Therapeutics Announce 2024 Promotional..
24/1/202408:00GLOBEEsperion Announces Closing of Public Offering of Common..
22/1/202422:10EDGAR2Form 8-K - Current report
22/1/202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202413:15GLOBEEsperion Announces Pricing of $85.1 Million Public Offering..
19/1/202408:03EDGAR2Form 8-K - Current report
19/1/202408:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202408:00GLOBEEsperion Announces Proposed Public Offering of Common Stock
12/1/202408:09EDGAR2Form 8-K - Current report
04/1/202407:15BWEsperion e Daiichi Sankyo Europe annunciano un emendamento..
04/1/202405:54BWEsperion et Daiichi Sankyo Europe annoncent une révision de..
04/1/202402:07BWEsperion und Daiichi Sankyo Europe geben Anpassung ihrer..
04/1/202400:00EDGAR2Form 8-K - Current report
03/1/202423:00BWEsperion and Daiichi Sankyo Europe Announce $125 Million..
19/12/202300:00GLOBEEsperion to Participate in 42nd Annual J.P. Morgan..
14/12/202308:46DJNEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA..
14/12/202308:00GLOBEU.S. FDA Updates LDL-C Lowering Indication for Esperion’s..
14/11/202302:30GLOBEEsperion Presents CLEAR Outcomes Analysis of Inflammation as..
12/11/202303:00GLOBEPartners Announce TRANSFORM Trial to Evaluate Personalized..
10/11/202308:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
08/11/202300:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:30EDGAR2Form 8-K - Current report
07/11/202322:00GLOBEEsperion Reports Third Quarter 2023 Financial Results
31/10/202323:00GLOBEEsperion to Participate in Jefferies London Healthcare..
24/10/202323:00GLOBEEsperion to Report Third Quarter 2023 Financial Results on..
06/10/202300:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
22/9/202307:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202305:22EDGAR2Form 144 - Report of proposed sale of securities
13/9/202300:15GLOBEAmerican College of Cardiology Program to Increase..
28/8/202322:00GLOBEEsperion to Participate in H.C. Wainwright 25th Annual..
27/8/202301:00GLOBEEsperion Presents Two CLEAR Outcomes Study Late-Breakers at..
24/8/202323:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/8/202306:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/8/202305:31EDGAR2Form 144 - Report of proposed sale of securities

Your Recent History

NASDAQ
ESPR
Esperion Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved